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Abstract p190 RhoGAP is a multi-domain protein that is
thought to regulate actin cytoskeleton dynamics. It can be
phosphorylated both in vitro and in vivo at multiple sites by the
Src tyrosine kinase and one or more of these sites is postulated to
modulate p190 function. One of the regions which is multiply
phosphorylated by Src in vitro is the N-terminal GTP binding
domain. Using a partially purified, bacterially expressed
recombinant protein that includes the GTP binding domain
(residues 1^389), we show that GTP binds to this fragment in a
specific and saturable manner that is both time- and dose-
dependent and that tyrosine phosphorylation of this fragment by
c-Src results in a loss of GTP binding activity. These findings
suggest that tyrosine phosphorylation of the p190 N-terminal
domain can alter its ability to bind GTP.
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1. Introduction
p190 RhoGAP is a 190 kDa protein that was ¢rst identi¢ed
as a tyrosine phosphorylated protein that co-immunoprecipi-
tated with p120 RasGAP [1]. Molecular cloning of p190
cDNA revealed homologies in the N-terminal 250 amino acids
with GTP binding proteins and in the C-terminal region with
GTPase activating proteins for Rho family members (Fig. 1A
[2,3]). GTP binding proteins and RhoGAPs have been asso-
ciated with regulating actin dynamics, suggesting that p190
may also be involved in such activities [4]. Furthermore, ty-
rosine phosphorylation of p190 appears to provide a link
between tyrosine kinase growth factor receptors, Ras signaling
pathways (through RasGAP) and cytoskeleton remodeling.
Studies in C3H10T1/2 murine ¢broblasts showed that p190
RhoGAP and p120 RasGAP undergo transient, simultaneous
re-distribution following epidermal growth factor stimulation
and that this re-distribution correlates temporally and spa-
tially with actin stress ¢ber dissolution [5]. Tyrosine phosphor-
ylation of p190 by c-Src was also shown to co-ordinately
regulate p190/p120 re-distribution and actin remodeling in
an EGF-dependent manner. These ¢ndings led to the hypoth-
esis that tyrosine phosphorylation could exert its e¡ect on
these processes through modulation of the GTP binding or
RhoGAP activities of p190 N-terminal or C-terminal do-
mains, respectively. The primary site of p190 tyrosine phos-
phorylation is Tyr 1105, which lies just upstream of the Rho-
GAP domain [6,7]. Phosphorylation of Tyr 1105 promotes
p120 Ras GAP binding to p190 both in vitro and in vivo
[6,7] and plays a role in vivo in modulating the activity of
the p190 RhoGAP domain (Haskell et al., in preparation).
However, other sites (as yet unidenti¢ed) are also phosphor-
ylated in vivo and in vitro, particularly by v-Src [6], an onco-
protein that causes striking alterations in intracellular actin
cytoskeleton structures [8]. Because there was precedence for
tyrosine phosphorylation of GTP binding proteins having ef-
fects on their activities (see Section 4), we sought to determine
if the ability of the isolated N-terminal domain to bind GTP
in vitro might be a¡ected by c-Src-mediated tyrosine phos-
phorylation. We found that tyrosine phosphorylation of the
N-terminal domain by c-Src resulted in a decreased ability of
this domain to bind GTP.
2. Materials and methods
2.1. Construction of p190 N-terminal bacterial expression plasmid
Full-length wt p190 cDNA (Fig. 1A) was excised from pBluescript
(a gift of J. Settleman) by digestion with BamHI and EcoRV and
inserted into the pRSET A bacterial expression plasmid (Invitrogen,
Carlsbad, CA, USA) at the compatible restriction sites, BamHI and
PvuII. This construct (p190pRSET) encoded p190 that was hexahis-
tidine tagged at the amino terminus. P190pRSET was then digested
with NcoI, which resulted in the excision of the 3P two-thirds of the
p190 coding sequence and the formation of a fragment (retained in
the plasmid backbone) that encoded the ¢rst 389 amino acids of p190.
This fragment was isolated, self-ligated and transformed into the
VDE3 lysogen of Escherichia coli BL21 for propagation and expres-
sion. A mutant form of this construct that was defective for GTP-
binding was generated by substituting D for K201 and V for D203
(Fig. 1A), using the Quickchange mutagenesis kit from Stratagene.
These residues are contained within the guanine nucleotide binding
loop and the alteration of homologous residues in other GTP binding
proteins has been shown to disrupt guanine nucleotide binding [9,10].
2.2. Expression and puri¢cation of p190 N-terminal domain
BL21/DE3 transformants were grown in LB media containing 50
Wg/ml ampicillin at 37‡C to an OD600 of approximately 1.0, at which
point they were induced with 1 mM isopropyl L-D-thiogalactopyrano-
side (IPTG; Sigma) for 3 h. The bacteria were harvested by centrifu-
gation and pellets were resuspended in chilled binding bu¡er (20 mM
Tris^HCl, pH 7.9, 500 mM NaCl, 5 mM imidazole, 0.01% NP-40,
aprotinin, leupeptin and 1 mM PMSF). The suspension was pulse-
sonicated on ice for 1 min to shear chromosomal DNA and cellular
debris was pelleted by centrifugation at 10 000 rpm for 30 min in a
Sorvall SS34 rotor. These and subsequent puri¢cation steps were car-
ried out at 4‡C. Supernatant, which contained the p190 N-terminal
domain, was passed over a 2 ml bed volume Ni2 charged resin
(Novagen, Madison, WI, USA) at a £ow rate of 20 ml/h. The column
was then washed with 25 ml binding bu¡er, followed by a wash in 100
ml of binding bu¡er containing 60 mM imidazole. The protein bound
to the Ni2 resin was then eluted with 10 ml binding bu¡er containing
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1 M imidazole. One ml fractions were collected and analyzed by SDS^
PAGE and Coomassie Blue staining or Western blotting to determine
the fractions which contained the N-terminal domain. Protein concen-
trations of pooled fractions were determined by the bicinchoninic acid
assay (Pierce Chemical Co., Rockford, IL, USA). BL21/DE3 trans-
formants of the pRSET vector without insert were grown and proc-
essed identically to serve as controls for GTP binding.
2.3. Western immunoblotting
All steps were performed at room temperature. Proteins separated
by SDS^PAGE were transferred to Immobilon-P PVDF membrane
(Millipore, Bedford, MA, USA). The membrane was then incubated
for 1 h in blocking bu¡er (4% bovine serum albumin (BSA) in Tris-
bu¡ered saline containing 0.1% Tween 20) and for an additional hour
in blocking bu¡er containing 5 Wg/ml puri¢ed, mouse monoclonal
antibody (mAb) 8C10, which is speci¢c for p190 [5,11]. To localize
bound primary antibody, the membrane was incubated with 125I-la-
beled goat anti-mouse IgG (New England Nuclear (NEN), Boxton,
MA, USA) at a concentration of 1 WCi/ml in blocking bu¡er. The
membrane was then washed three times for 5 min each in TBS with
0.1% Tween 20, air dried and subjected to autoradiography.
2.4. GTP overlay assay
This assay was carried out as described by Wagner et al. [12].
Brie£y, 1^5 Wg Ni2-column puri¢ed, His-tagged p190 N-terminal
domain or equivalent control eluate from vector-alone extracts was
separated by SDS^PAGE on a 7% gel. The gel was then incubated in
1 l 50 mM Tris^HCl, pH 7.5, 20% (v/v) glycerol for 30 min at room
temperature. Using a Trans-Blot cell (Bio-Rad), proteins were trans-
ferred overnight at 150 mA, 4‡C to nitrocellulose membranes, which
were submerged in a bu¡er consisting of 10 mM NaHCO3/3 mM
Na2CO3, pH 9.8, to allow for protein renaturation. The membrane
was then rinsed twice in 20 ml GTP binding bu¡er (50 mM NaH2PO4,
pH 7.5, 10 WM MgCl2, 2 mM DTT, 0.3% (v/v) Tween 20, 4 WM ATP)
for 10 min each and incubated in 20 ml GTP binding bu¡er contain-
ing 40 WCi [K-32P]GTP (3000 Ci/mmol, 10 mCi/ml; Dupont/NEN,
Boston, MA, USA) for 2 h. The membrane was then washed six times
for 2^5 min each in GTP binding bu¡er, dried and exposed to X-ray
¢lm.
2.5. GTP solution binding assay
The GTP solution binding assay was adapted from Tisdale et al.
[13] and Graber et al. [14]. Approximately 1 pmol Ni2-column puri-
¢ed, His-tagged p190 N-terminal domain, an equivalent volume of a
Ni2-column eluate from a vector-only control lysate or V1 pmol of
a partially puri¢ed preparation of the K subunit of the heterotrimeric
G protein, Gi3 (a gift of J. Garrison [14] were incubated with 1 WCi [Q-
35S]GTP (1250 Ci/mmol, Dupont/NEN, Boston, MA, USA, adjusted
to 1 WCi/445 pmol with cold GTP) in a bu¡er containing 75 mM Na-
HEPES, pH 8.0, 100 mM NaCl, 10 mM MgCl2, 0.5 mM ATP and
1 mM EGTA (binding bu¡er) in a total volume of 200 Wl for the
indicated times at 30‡C. The reaction was terminated by the addition
of 1 ml chilled bu¡er containing 50 mM Tris^HCl, pH 8.0, 100 mM
NaCl and 25 mM MgCl2 (stop bu¡er) and placing the samples on ice.
Samples were then ¢ltered through 100 mm PVDF membrane discs
(Millipore) and washed with 10 ml of a solution containing 25 mM
Tris, 100 mM NaCl and 30 mM MgCl2 (wash bu¡er). After air dry-
ing, the amount of labeled nucleotide bound to the ¢lter was deter-
mined by scintillation counting. For dose dependency and competi-
tion assays, indicated concentrations of various nucleotides were
added to the binding bu¡er containing [Q-35S]GTP, and in competition
studies, ATP was removed entirely from this bu¡er.
2.6. Src phosphorylation of p190 N-terminal domain
Prior to the kinase reaction, imidazole was removed from the prep-
aration of p190 protein by either equilibrium dialysis in 50 mM Tris^
HCl, pH 7.2, 150 mM NaCl or by gel ¢ltration using a PD-10 column
(Pharmacia). Approximately 1 Wg Ni2-column puri¢ed p190 N-ter-
minal domain was then incubated for 30 min in kinase reaction bu¡er
(50 mM Tris^HCl, pH 7.2, 100 WM cold ATP and 10 mM MgCl2) in
the presence or absence of 3 units baculovirus-expressed c-Src (UBI).
A soluble GTP binding assay was then carried out for 1 h with [Q-
35S]GTP, as described above, in the presence or absence of excess (10
WM) unlabeled GTP. To visualize phosphorylated proteins, V1 WCi
[Q-32P]ATP was included in a separate in vitro kinase reaction and
products were analyzed by SDS^PAGE and autoradiography.
2.7. Tryptic phosphopeptide mapping
Tryptic phosphopeptides of the in vitro phosphorylated p190 N-
terminal domain were generated and analyzed according to the meth-
od of Boyle et al. [15]. Peptides were separated on 10U10 cm thin
layer cellulose plates (E. Merck, Darmstadt, Germany) by electropho-
resis in the ¢rst dimension at 1500 V for 22 min in pH 1.9 bu¡er (2.2%
formic acid, 7.8% glacial acetic acid), using a Hunter thin-layer elec-
trophoresis unit (HTLE 7000; CBS Scienti¢c, Del Mark, CA, USA)
and by chromatography in the second dimension in isobutyric acid
bu¡er (isobutyric acid:n-butanol:pyridine:glacial acetic acid:H2O at
62.5:1.9:4.8:2.9:27.9, v/v/v/v). Separated phosphotryptic peptides
were visualized by autoradiography.
For determination of candidate sites phosphorylated by c-Src, the
entire tryptic digest of radiolabeled p190 N-terminal domain was an-
alyzed by C18 HPLC and isolated peptides were subjected to Edman
degradation according to the method of Shannon and Fox [16].
3. Results
3.1. GTP binding to the p190 GTPase domain
To initiate our investigation into the possible regulation by
tyrosine phosphorylation of the p190 N-terminal domain, we
¢rst wished to verify that the recombinant, puri¢ed protein
was capable of binding GTP in a speci¢c and saturable man-
ner. To this end, BL23/DE3 E. coli bacteria were transformed
with the pRSET expression vector encoding the His-tagged N-
terminal fragment of p190 (Fig. 1A) and the recombinant
protein was puri¢ed by Ni2 chromatography as described
in Section 2. The purity was assessed by Coomassie blue
staining. As a negative control, bacteria were transformed
with an empty vector, and the extract lacking recombinant
p190 was carried through the same puri¢cation scheme as
the extract with recombinant p190 protein. A mutant re-
combinant p190 N-terminal protein that contained K201D
and D203V substitutions known to disrupt guanine nucleotide
binding in other G proteins [9,10] was also generated and
puri¢ed in the same manner (Fig. 1A). Fig. 1B is a Coomassie
blue stain of the three preparations. Several contaminating
bands were seen to variable extents in the di¡erent prepara-
tions of p190 (compare lanes 1 and 3 with lane 2), but the
predominant product of the puri¢cation scheme migrated at
V50 kDa, the predicted size of the N-terminal recombinant
p190 domain. The wild type protein preparation frequently
contained several p190-speci¢c breakdown products, as as-
sessed by direct immunoblotting of the same panel of proteins
with mAb 8C10, a p190-speci¢c antibody [15] (Fig. 1C, lane
Table 1
P190 N-terminal domain preferentially binds GTP and GDPa












aSimilar results were obtained in two additional experiments using
1000-fold molar excess unlabeled nucleotide.
b2500 pmol of unlabeled competing nucleotide: 5 pmol [Q35S]GTP.
(500-fold excess).
cValues represent the average of two independent experiments.
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4). By the lack of 8C10 binding to the control preparation
(lane 5), contaminating proteins could be identi¢ed. Fig. 1C,
lane 6 shows that the GTP binding mutant was also puri¢ed
as a 50 kDa protein.
Fig. 1D depicts a GTP overlay assay in which protein prep-
arations were subjected to SDS^PAGE and transferred to a
nitrocellulose membrane in a bu¡er that allows for partial
renaturation of the proteins [12]. Following incubation of
the membrane with [K-32P]GTP, it was observed that only
the wt N-terminal domain binds GTP.
To determine the kinetics, dose-dependency and speci¢city
of this binding, a GTP solution binding assay was employed,
as described in Section 2. In these experiments, a partially
puri¢ed fraction containing the K subunit of the heterotrimer-
ic G protein, Gi3, was included as a positive control and the
empty vector preparation was used as a negative control. As
seen in Fig. 2A, the p190 N-terminal domain (residues 1^389)
bound GTP with kinetics similar to the positive control and to
a signi¢cantly greater extent than the negative control. Similar
results were obtained with a GST fusion protein containing
residues 29^240, which contains the core GTP binding sequen-
ces (data not shown, Fig. 1A and [19]). Fig. 2B shows that
binding to the p190 N-terminal domain was dose-dependent
and greater at all concentrations of nucleotide tested than the
negative control. The GTP binding seen with the negative
control likely represented a non-speci¢c interaction, as the
Fig. 2. Time-course and dose-dependency of GTP binding to the re-
combinant p190 N-terminal domain. A: Time-course of GTP bind-
ing. In a solution binding assay [Q-35S]GTP was incubated with ei-
ther 1 pmol p190 N-terminal domain (open squares), 1 pmol
partially puri¢ed Gi3K subunit (closed squares) or a volume of vec-
tor-only contaminating proteins equal to that used for the p190 do-
main (closed diamonds) for the indicated times. The p190 domain
bound GTP with a similar time-course and extent as Gi3K. At satu-
ration, 0.15 mol GTP was bound per mol p190 or mol Gi3K, sug-
gesting that V15% of each protein preparation was conformational-
ly active. Values represent the average of two data points. Similar
results were obtained in two additional experiments, except that the
amount of GTP bound at saturation varied from preparation to
preparation. B: Dose-dependency of GTP binding. One pmol p190
N-terminal domain was incubated with indicated concentrations of
unlabeled GTPQS for 60 min in a GTP solution binding bu¡er con-
taining [Q-35S]GTP, as described in Section 2. An equal volume of
the vector-only contaminant proteins exhibited a background level
of GTP binding. These data were reproduced in a separate experi-
ment.
Fig. 1. Recombinant, hexahistidine-tagged p190 N-terminal domain
binds GTP directly. A: Schematic of full-length p190 RhoGAP and
the N-terminal GTP binding domain used in this study (residues 1^
389). Full-length p190 contains an N-terminal GTP binding domain,
a large middle domain and a C-terminal RhoGAP domain. The
GTP binding domain, residues 29^240, contains three motifs found
in all GTP binding proteins, a phosphate-binding loop, a Mg2-
binding loop and a guanine nucleotide-binding loop. In addition,
p190 contains sequences that contribute to the GTP binding ca-
pacity of Ras and Rab family members. The consensus motif for
these regions, as well as the speci¢c residues found in p190, are
shown. Residues mutated in the guanine-binding loop are designated
with *. B: Coomassie blue staining of an SDS^PAGE gel containing
V3 Wg Ni2 chromatography-puri¢ed wt p190 N-terminal domain
(lane 1), vector only contaminating proteins (lane 2) and the
K201D, D203V mutant of the N-terminal domain (lane 3). Arrows
indicate the 50 kDa full-length, N-terminal fragment and two break-
down products. C: Western blot of the same samples depicted in
(A), blotted with the anti-p190 mAb, 8C10. D: GTP overlay assay.
The same samples were separated on SDS^PAGE, transferred to a
nitrocellulose membrane and probed with [K-32P]GTP as described
in Section 2. Longer exposure of the autoradiogram continued to
show no [K-32P]GTP binding in lane 9. These data are representa-
tive of two independent experiments.
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overlay assay ruled out the possibility that contaminant pro-
teins had GTP binding activity. To assess the nucleotide spe-
ci¢city of binding, a competition study was carried out, using
a panel of nucleotides as competitors for [Q-35S]GTP binding.
Table 1 shows that binding of [Q-35S]GTP was e¡ectively com-
peted by cold, excess GTPQS, GTP and GDP but not by
dGTP, GMP or other nucleotides or nucleosides. These re-
sults are similar to those obtained from nucleotide competi-
tion studies that examined the speci¢city of p21Ras GTPase
activity [17]. Also consistent with previous studies in which
full length p190 was examined [18], we were unable to detect
by thin layer chromatography analysis a GTPase activity that
was intrinsic to the isolated N-terminal domain (data not
shown).
3.2. E¡ect of Src phosphorylation on the p190 GTPase domain
To examine the possibility that tyrosine phosphorylation
could a¡ect the ability of the p190 N-terminal domain to
bind GTP, the recombinant His-tagged fusion protein was
incubated in kinase bu¡er in the presence or absence of c-
Src before subjecting it to a GTP solution binding assay as
described in Section 2. Fig. 3A shows a greater than 90%
decrease in the ability of the p190 N-terminal domain to
bind [Q-35S]GTP after phosphorylation by c-Src as compared
to the N-terminal domain incubated in kinase bu¡er alone,
while c-Src alone exhibited only background levels of GTP
binding. In a separate kinase reaction, p190 was radiolabeled
with [Q-32P]ATP to assess phosphorylated products by auto-
radiography (Fig. 3B). Autophosphorylation of c-Src and
transphosphorylation of the p190 N-terminus and several
breakdown products were observed. Phosphoamino acid anal-
ysis [15] revealed that only tyrosine residues were phosphory-
lated (data not shown). Fig. 3C is a tryptic phosphopeptide
map that demonstrates the complex nature of the phosphor-
ylation pattern. Six phosphopeptides were routinely observed,
and four (Fig. 3A^D) were successfully puri¢ed by HPLC and
shown to co-migrate with tryptic phosphopeptides of in vivo
32P-labeled p190 from v-Src transformed murine ¢broblasts
(data not shown). Fig. 3D lists the potential sites of phosphor-
ylation by c-Src as determined by sequential Edman degrada-
tion of HPLC-isolated peptides and coincidence of the cycle
number of peak 32P release with the position of tyrosine res-
idues in tryptic peptides derived from the N-terminal domain
of p190. Peptides E and F were refractory to HPLC analysis.
Fig. 3. Tyrosine phosphorylation of the p190 GTPase domain by c-Src inhibits GTP binding. A: GTP solution binding assay. Ni2 resin-puri-
¢ed p190 N-terminal domain was incubated in kinase reaction bu¡er in the presence or absence of baculovirus expressed c-Src (UBI) and then
assessed for the ability to bind [Q-35S]GTP in the presence or absence of excess unlabeled GTP, as described in Section 2. This result was ob-
served in two separate experiments, each performed in triplicate. B: Products of the kinase reaction. [Q-32P]ATP (V1 WCi) was included in the
in vitro kinase reaction and phosphorylated proteins were visualized by SDS^PAGE and autoradiography. C: Tryptic phosphopeptide map of
the p190 N-terminal domain. The P190 N-terminal domain was phosphorylated in vitro by c-Src in the presence of [Q-32P]ATP and subjected
to tryptic phosphopeptide analysis as described in Section 2. V2000 cpm were loaded on the TLC plate. D: Candidate phosphopeptides of the
p190 N-terminal domain phosphorylated by c-Src. HPLC-puri¢ed tryptic phosphopeptides were subjected to sequential Edman degradation
analysis and the cycle number at which maximum 32P was released was matched to the tyrosine position within theoretical tryptic peptides of
the p190 N-terminal domain, according to the method of Boyle et al. [15].
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4. Discussion
The data presented above demonstrate that the p190 N-
terminal domain can be phosphorylated in vitro by c-Src,
that the isolated, recombinant p190 protein binds GTP di-
rectly and speci¢cally in a time- and dose-dependent manner
and that phosphorylation by c-Src results in greater than 90%
loss of GTP binding activity. While others have reported that
full-length p190 binds GTP [18,19], this study is the ¢rst to
describe an e¡ect of tyrosine phosphorylation on GTP bind-
ing. Multiple sites are phosphorylated in the N-terminal do-
main by c-Src (Fig. 3C), but it is not known whether one or
more of these sites is required for the e¡ect or what the mech-
anism of inhibition may be. Y116 and Y133 are prime candi-
dates for further investigation, since they reside within the
GTP binding domain itself and Y133 is near the critical
Mg2 binding loop.
The stoichiometry of p190 N-terminal domain phosphory-
lation by c-Src was found to be V10%. Similarly, relatively
low stoichiometries have previously been observed by us and
others in studies with bacterially expressed K subunits of het-
erotrimeric G proteins [20]. Although we are uncertain as to
the reason for these ¢ndings, we did experience some di⁄cul-
ties with the solubility of several p190 preparations, suggesting
that only a portion of the protein was completely renatured
following Ni2 chromatography. However, the number of mo-
les of phosphate incorporated into the p190 N-terminus was
approximately equal to the number of moles of GTP bound
to the unphosphorylated protein in these preparations, sug-
gesting that the portion of p190 protein that assumed a native
conformation was capable of either binding GTP or becoming
phosphorylated.
Functional e¡ects of tyrosine phosphorylation on other
GTP-binding proteins have previously been described. For
example, tyrosine phosphorylation mediated by the EGF re-
ceptor of a 22 kDa GTP binding protein (G25K) from brain
was found to result in a small but signi¢cant increase in GTP
binding when the protein was reconstituted into phospholipid
vesicles [21]. In A431 cells, EGF treatment suppressed brady-
kinin-induced activation of the cAMP pathway via tyrosine
phosphorylation of GsK [22] and tyrosine phosphorylation of
the Gq/G11 K subunit by v-Src was shown to lead to an
increase in the ability of the K subunit to stimulate PLC-L
in vitro [23]. In another study, phosphorylation of GqK at
Tyr 356 was found to be required for optimal inositol-1,4,5-
trisphosphate (IP3) production following stimulation by mul-
tiple agonists of Gq/11-coupled receptors [24].
What role the GTP-binding domain of p190 plays in cell
physiology is not yet clear. One potential role for the p190
GTP binding domain is to provide another site in the p190
molecule (in addition to the RhoGAP domain), by which ty-
rosine phosphorylation can a¡ect actin cytoskeleton dynam-
ics. As yet, no direct evidence for the involvement of the p190
GTP binding domain in this process has been forthcoming.
However, the GTP binding domain of p190 has been shown
to play a role in inducing cell morphology changes upon over-
expression of full length p190 [19] and in reversing anchorage-
independent growth of Ras-transformed cells [25]. Since both
these processes involve changes in actin cytoskeleton struc-
tures, it is reasonable to speculate that the p190 GTP binding
domain is involved in such events. In addition, recent studies
in our laboratory suggest that the GTP binding domain is
required, but not su⁄cient for p190-induced cell cycle arrest
(Dukes et al., in preparation). Thus, the GTP binding domain
of p190 could play a role in regulating several cellular pro-
cesses, which in turn could be modulated by tyrosine phos-
phorylation.
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